PD-1信号通路在非小细胞肺癌中的研究进展

Research progress of PD-1 pathway in non-small-cell lung cancer

免疫治疗是目前除手术、化疗、放疗及靶向治疗外,另一种能够有效改善肺癌预后的治疗方法。在各种免疫治疗方法中,免疫检查点抑制剂(immune checkpoint inhibitors,ICI)在近年来发展迅速,已成为肿瘤治疗领域的新兴疗法及研究热点。其中,程序性死亡受体1(programmed death receptor-1,PD-1)及其配体程序性死亡配体-1(programmed death receptor-ligand1,PD-L1)的抑制剂在多种恶性肿瘤的治疗中均取得了显著疗效,部分药物已被美国FDA批准应用于临床。该文对PD-1/PD-L1抑制剂在晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者治疗中的临床研究现状进行综述,探讨其在晚期NSCLC治疗中的临床应用价值、前景及面临的问题与挑战。

Immunotherapy is a new method which improves the prognosis of lung cancer effectively,in addition to surgery therapy,chemotherapy,radiotherapy and targeted therapy.In recent years,the amount of researches on immune checkpoint inhibitors has grown sharply which has become a hotspot for researchers.The inhibitors of programmed death receptor-1(PD-1)and its ligand programmed death receptor-ligand 1(PD-L1)have achieved significant effects in multiple malignancies.Some of them have been approved for clinical treatments by FAD.This paper will review the research advances on PD-1/PD-L1 pathway inhibitors for the treatment of non-small-cell lung cancer.